Soluble epoxide hydrolase (sEH) converts epoxides to their corresponding diols. Inhibitors of sEH have anti-inflammatory, anti-hypertensive, neuroprotective, and cardioprotective effects. TPPU is a potent inhibitor of both human and mouse sEH (IC50 = 3.7 and 2.8 nM, respectively). The pharmacokinetics of this compound are dramatically superior to those of the 1-adamantylurea based inhibitors, like AUDA.
